- Home
- CPB vs QGEN Comparison
CPB vs QGEN Comparison
Compare CPB & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPB
- QGEN
- Stock Information
- Founded
- CPB 1869
- QGEN 1986
- Country
- CPB United States
- QGEN Netherlands
- Employees
- CPB N/A
- QGEN N/A
- Industry
- CPB Packaged Foods
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPB Consumer Staples
- QGEN Health Care
- Exchange
- CPB Nasdaq
- QGEN Nasdaq
- Market Cap
- CPB 11.9B
- QGEN 9.9B
- IPO Year
- CPB N/A
- QGEN 1996
- Fundamental
- Price
- CPB $39.92
- QGEN $40.16
- Analyst Decision
- CPB Hold
- QGEN Buy
- Analyst Count
- CPB 16
- QGEN 8
- Target Price
- CPB $45.00
- QGEN $49.79
- AVG Volume (30 Days)
- CPB 4.2M
- QGEN 1.1M
- Earning Date
- CPB 03-05-2025
- QGEN 04-28-2025
- Dividend Yield
- CPB 3.89%
- QGEN 3.31%
- EPS Growth
- CPB N/A
- QGEN N/A
- EPS
- CPB 1.73
- QGEN 0.37
- Revenue
- CPB $10,119,000,000.00
- QGEN $1,978,214,000.00
- Revenue This Year
- CPB $8.01
- QGEN $5.15
- Revenue Next Year
- CPB N/A
- QGEN $6.49
- P/E Ratio
- CPB $23.16
- QGEN $107.70
- Revenue Growth
- CPB 9.15
- QGEN 0.66
- 52 Week Low
- CPB $36.92
- QGEN $37.63
- 52 Week High
- CPB $52.81
- QGEN $47.93
- Technical
- Relative Strength Index (RSI)
- CPB 55.08
- QGEN 53.09
- Support Level
- CPB $37.75
- QGEN $39.35
- Resistance Level
- CPB $38.48
- QGEN $40.11
- Average True Range (ATR)
- CPB 0.78
- QGEN 0.53
- MACD
- CPB 0.11
- QGEN 0.20
- Stochastic Oscillator
- CPB 76.41
- QGEN 92.43
About CPB Campbell Soup Company
Over the past 150-plus years, Campbell has evolved into a leading packaged food manufacturer in North America, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2024, snacks accounted for nearly half of its revenue, followed by soup (28%), other simple meals (17%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in March 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).